{"id":16156,"date":"2021-03-02T14:03:54","date_gmt":"2021-03-02T13:03:54","guid":{"rendered":"https:\/\/www.izb-online.de\/leukocare-und-malvern-kooperieren-bei-stabilisierung-und-formulierung-im-rahmen-der-entwicklung-von-covid-19-impfstoffen\/"},"modified":"2021-03-15T12:19:44","modified_gmt":"2021-03-15T11:19:44","slug":"leukocare-und-malvern-kooperieren-bei-stabilisierung-und-formulierung-im-rahmen-der-entwicklung-von-covid-19-impfstoffen","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/leukocare-and-malvern-collaborate-on-stabilization-and-formulation-for-covid-19-vaccine-development\/","title":{"rendered":"Leukocare and Malvern collaborate on stabilization and formulation for COVID-19 vaccine development"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Leukocare and Malvern collaborate on stabilization and formulation for COVID-19 vaccine development<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine-lead”]Leukocare AG and Malvern Panalytical Ltd today announced on March 1, 2021 an exciting collaboration which will improve the availability of vaccines for COVID-19. They will combine Leukocare\u2019s pioneering expertise in biopharmaceutical formulation development with Malvern Panalytical\u2019s extensive analytical knowhow to understand how the stability of vaccines can be improved, increasing production and simplifying distribution.[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]March 2021[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_single_image image=”16152″ img_size=”full”][vc_column_text el_class=”gco-magazine-copyright”]\u00a9 LEUKOCARE AG[\/vc_column_text][vc_column_text el_class=”gco-magazine-picture-discription”]\u201cOur collaboration with Malvern Panalytical will help us to work even better on our ongoing and future projects to achieve stability improvements for a range of vaccines,\u201d explains Dr. Andreas Seidl, Chief Operating Officer Leukocare AG[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote” css=”.vc_custom_1611310713611{margin-top: 33px !important;}”][vc_column_inner][vc_column_text]<\/p>\n

\u201cOur collaboration with Malvern Panalytical will help us to work even better on our ongoing and future projects to achieve stability improvements for a range of vaccines.\u201d<\/h6>\n

Dr. Andreas Seidl
\nChief Operating Officer Leukocare AG<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy” css=”.vc_custom_1591795890737{margin-top: 21px !important;}”][vc_column_inner][vc_column_text]Dr. Andreas Seidl, Chief Operating Officer at Leukocare, commented, \u201cI am excited and thankful to start this collaboration in these unprecedented times. While we have already seen tremendous efforts and several successes on approvals of vaccines targeting the COVID-19 pandemic in the past few months, there still is a high unmet need for improved stability, supply and storage conditions to serve the vast majority of people and countries over the upcoming months and years. Our collaboration with Malvern Panalytical will help us to work even better on our ongoing and future projects to achieve stability improvements for a range of vaccines.\u201d<\/p>\n

Mark Fleiner, President of Malvern Panalytical, also expressed excitement about the opportunities presented by this project. \u201cWe have all experienced the impact of the current COVID-19 pandemic on the lives of our families, friends and work colleagues\u201d stated Mark. \u201cThe availability of vaccines brings hope to us all \u2013 so we jumped at the opportunity to be involved in this deep collaboration with Leukocare working together to understand how vaccine stability can be improved and ensure wider availability.\u201d<\/p>\n

About Leukocare AG
\n<\/strong>Leukocare AG, located in the Innovation and Start-ups Center Biotechnology (IZB) in Martinsried\/Munich, Germany, is a biotechnology company specialized in the field of biopharmaceutical formulation development. Operating at the interface of drug substance and drug product development, Leukocare combines sound knowledge of formulation development with bioinformatics and artificial intelligence. The formulation development approach consists of two elements: a library of up to 100 different regulatory well-established and employed excipients and a rational development approach which employs statistical software and self-learning algorithms as well as state of the art design of experiment (DoE) matrices. By utilizing the artificial intelligence elements, Leukocare is able to specifically combine excipients leading to stabilizing formulations tailored to the drug product\u2019s needs. Leukocare\u2019s superior and innovative drug product formulations can be applied to a broad range of applications: biologics & biosimilars, vaccines & viral vectors and biofunctionalized devices.<\/p>\n

\u00a0<\/strong>About the technology
\n<\/strong>Profiling and optimization of colloidal and thermal stability of biologics is at the center of Malvern Panalytical\u2019s technical solutions and expertise, with Dynamic Light Scattering, multi-detector size-exclusion chromatography, and Differential Scanning Calorimetry (DSC) providing the complementary data required to drive formulation development. MicroCal DSC is a gold standard technique for assessing thermal stability and facilitating the selection of stable formulations and has been used in the development of a wide range of biologics from recombinant proteins and vaccines to viral vectors and lipid-based drug delivery systems.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n